TFRC and cancer: Ru(II) complexes have emerged as promising alternatives to platinum-based chemotherapeutics, offering distinct advantages such as low systemic toxicity, activity against cisplatin-resistant cancers, and selectivity for cancer cells, often through the exploitation of overexpressed transferrin receptors [78,79].